Clinafloxacin

Clinafloxacin

SCHEMBL33960

N[C@H]1CCN(c2c(F)cc3c(=O)c(C(=O)O)cn(C4CC4)c3c2Cl)C1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 1.00
POLB P06746 2/20 1.00
OPRM1 P35372 2/20 1.00
CHRM2 P08172 1/20 1.00
CHRM1 P11229 1/20 1.00
OPRD1 P41143 1/20 1.00
KCNH2 Q12809 4/20 0.61
CYP3A4 P08684 1/20 0.56
CYP2C9 P11712 1/20 0.56
TOP2A P11388 9/20 0.56
TOP2B Q02880 7/20 0.56
KDM4E B2RXH2 1/20 0.55
PRKD3 O94806 1/20 0.55
HPGD P15428 1/20 0.55
ALOX15 P16050 1/20 0.55
CLK2 P49760 1/20 0.55
HSD17B10 Q99714 1/20 0.55
CLK4 Q9HAZ1 1/20 0.55
TDP1 Q9NUW8 1/20 0.55
TOP1 P11387 4/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Clinafloxacin SCHEMBL29360508 1.00 ALDH1A1 (1.00) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL8596801 1.00 ALDH1A1 (1.00) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL33959 1.00 ALDH1A1 (1.00) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL29682535 0.99 ALDH1A1 (0.98) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL5571098 0.99 ALDH1A1 (0.98) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL193234 0.99 ALDH1A1 (0.98) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL193233 0.99 ALDH1A1 (0.98) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL29288561 0.99 ALDH1A1 (0.98) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL14973954 0.98 ALDH1A1 (0.96) ALDH1A1POLBOPRM1CHRM2CHRM1
Clinafloxacin SCHEMBL8566142 0.96 ALDH1A1 (0.93) ALDH1A1POLBOPRM1CHRM2CHRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Appears in 8047 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12624057-B2 Bisphosphonate quinolone conjugates and uses thereof BIOVINC, LLC (US) 2026-05-12 US claimed
US-20260108619-A1 CONJUGATION LINKERS, CELL BINDING MOLECULE-DRUG CONJUGATES CONTAINING THE LINKERS, METHODS OF MAKING AND USES SUCH CONJUGATES WITH THE LINKERS HANGZHOU DAC BIOTECH CO., LTD. (CN) 2026-04-23 US claimed
EP-4434588-B1 AEROSOL DELIVERY DEVICE PARI PHARMA GMBH (DE) 2026-04-08 EP claimed
US-12576124-B2 Formulation of a conjugate of a tubulysin analog to a cell-binding molecule HANGZHOU DAC BIOTECH CO., LTD (CN) 2026-03-17 US claimed
EP-4659014-A1 EMULSION-BASED THICK-FILM ANTIFOULING COATING FOR HIGHLY SENSITIVE ELECTROCHEMICAL SENSING President And Fellows Of Harvard College (US) 2025-12-10 EP claimed
US-20250339551-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE DIFFERENT FUNCTIONAL SMALL MOLECULES FOR ENHANCED TREATMENT OF REFRACTORY DISEASES HANGZHOU SEEHE BIOTECHNOLOGY CO., LTD (CN) 2025-11-06 US claimed
EP-4642484-A1 TARGETED TREATMENT OF PROSTATE CANCERS AND OTHER TUMORS BY AN ANTIBODY-DRUG CONJUGATE Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4642492-A1 AN ANTIBODY-DRUG CONJUGATE HAVING TWO OR MORE FUNCTIONAL SMALL MOLECULE COMPOUNDS FOR ENHANCED TREATMENT OF REFRACTORY DISEASES Hangzhou Seehe Biotechnology Co., Ltd (CN) 2025-11-05 EP claimed
EP-4571306-A1 STABILIZING OXYGEN IN A COMPOSITION Instrumentation Laboratory Company (US) 2025-06-18 EP claimed
CN-120142412-A Stabilizing oxygen in a composition 仪器实验室公司 2025-06-13 CN claimed
WO-2000061549-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
WO-2000061541-A2 PHARMACEUTICAL COMPOUNDS NICOX S.A. (FR) 2000-10-19 WO claimed
CN-1264430-A Betaines as adjuvants to susceptibility testing and antimicrobial therapy INTEGRATED RES TECHNOLOGY PLC (US) 2000-08-23 CN claimed
EP-1017402-A1 CONTROL OF ACIDIC GUT SYNDROME UNIVERSITY OF NEW ENGLAND (AU) 2000-07-12 EP claimed
WO-2000032196-A2 INHIBITORS OF MULTIDRUG TRANSPORTERS INFLUX, INC. (US) 2000-06-08 WO claimed
WO-2000024932-A1 METHODS OF IDENTIFYING AND CHARACTERIZING MUTATIONS WITHIN BACTERIAL DNA GYRASE AND FABI WARNER-LAMBERT COMPANY (US) 2000-05-04 WO claimed
EP-0980438-A1 BETAINES AS ADJUDVANTS TO SUSCEPTIBILITY TESTING AND ANTIMICROBIAL THERAPY Integrated Research Technology, LLC (US) 2000-02-23 EP claimed
WO-1999000136-A1 CONTROL OF ACIDIC GUT SYNDROME THE UNIVERSITY OF NEW ENGLAND (AU) 1999-01-07 WO claimed
WO-1998050576-A1 BETAINES AS ADJUVANTS TO SUSCEPTIBILITY TESTING AND ANTIMICROBIAL THERAPY INTEGRATED RESEARCH TECHNOLOGY, LLC (US) 1998-11-12 WO claimed
US-5532239-A FOR THE TREATMENT OF NEPHROTIC SYNDROMES ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (FR) 1996-07-02 US claimed